Sobi, Biogen’s haemophilia B therapy gets European approval
May 13, 2016Medical Communications, Research and Development, Sales and Marketing Biogen, haemophilia B, orphan designation, regulation, sobi
Sobi (STO: SOBI) and Biogen (Nasdaq: BIIB) on Friday said the European Commission has approved their drug to treat haemophilia B. The …
Bayer terminates clinical trial for hypertension due to safety concerns
May 13, 2016Medical Communications, Research and Development Bayer, clinical trial, deaths, pulmonary hypertension, riociguat, safety concerns
Bayer has terminated a Phase II trial evaluating riociguat in patients with pulmonary hypertension due to fears raised by an …
Takeda appoints new chief financial officer
May 12, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Takeda, cfo, james kehoe
Takeda Pharmaceuticals has named James Kehoe its new chief financial officer. He will begin the role on June 15 2016, …
Almost 9 in 10 CCGs not implementing NICE guidelines on antibiotic resistance
May 12, 2016Research and Development, Sales and Marketing CCGs, NICE, antibiotic resistance, failure
The Patients Association has called on all Clinical Commissioning Groups (CCGs) to implement the National Institute for Health and Care …
BMS says Nice refuses backing for its immunotherapy Opdivo to treat lung cancer
May 12, 2016Medical Communications, Research and Development, Sales and Marketing
The National Institute for Health and Care Excellence (Nice) has rejected US pharma firm Bristol-Myers Squibb’s (NYSE: BMY) immune-oncology drug …
Multiple myeloma treatment from BMS and AbbVie scores EU approval
May 12, 2016Research and Development, Sales and Marketing AbbVie, BMS, EMA, EU, Empliciti, approval, bristl-myers squibb, elotuzumab, multiple myeloma
Bristol-Myers Squibb (NYSE: BMY) and AbbVie (NYSE: ABBV) have announced that the European Commission has approved Empliciti (elotuzumab) for the …
FDA issues warning about rare, but serious, side effect in Lilly antipsychotic drug
May 12, 2016Medical Communications, Sales and Marketing Eli Lilly, FDA, anti-psychotic, boxed warning, lilly, olanzapine, skin condition
The US Food and Drug Administration (FDA) has issued a new warning to all drug labels for Eli Lilly’s antipsychotic …
AstraZeneca says its trial drug for thyroid cancer granted US FDA orphan drug designation
May 12, 2016Research and Development, Sales and Marketing AstraZeneca, Orphan Drug Designation, US FDA, drug trial, regulation
AstraZeneca (LSE: AZN) on Thursday said the US Food and Drug Administration (FDA) has granted Orphan Drug Designation its trial …
Nice recommends two blood tests to rule out pre-eclampsia in pregnant women
May 11, 2016Medical Communications, Sales and Marketing NICE, Roche, regulation
The National Institute for Health and Care Excellence (Nice) has backed two blood tests to help rule-out a complication in …
Nice backs GSK’s lupus drug Benlysta
May 11, 2016Research and Development, Sales and Marketing GSK, NHS, NICE, regulation
The National Institute for Health and Care Excellence (Nice) has backed GlaxoSmithKline’s (LSE: GSK) Benlysta (belimumab) to treat lupus. The …
Gilead’s Sovaldi gets Indian patent; critics call it “major blow” to patient access
May 11, 2016Manufacturing and Production, Research and Development, Sales and Marketing India, harm, hepatitis, patent, patient access, sovaldi
Gilead has been granted a patent for its hepatitis C drug, Sovaldi (sofosbuvir), in India which has sparked dismay among …
Santen Pharmaceutical says eye allergy drug meets primary endpoints in Phase III trials
May 11, 2016Research and Development, Sales and Marketing Eye Allergy, Santen Pharmaceutical, drug trial, phase III
Santen Pharmaceutical said late stage trials for its drug to treat an allergic eye condition in children met its primary …
Allergan to buy back $10 billion of stock, Q1 earnings rise
May 11, 2016Research and Development, Sales and Marketing Allergan, Buy Back, Financial, Q1, earnings, results, revenue
Botox-maker Allergan (NYSE: AGN) said it plans to buy back as much as $10 billion in stock after completing the …
FDA expands Imbruvica label with new survival data
May 11, 2016Research and Development, Sales and Marketing AbbVie, FDA, Janssen, data, efficacy, expanded, imbruvica, label, late stage, phase III
The US Food and Drug Administration (FDA) has expanded the label of Imbruvica (ibrutinib) to include the data from recent …
Baxalta sues Chugai for haemophilia drug patent breach
May 11, 2016Research and Development Baxalta, Chugai, breach, court, haemophilia, infringe, infringement, patent, sue, suing
Baxalta has taken Chugai Pharmaceuticals to the Tokyo district court, claiming that the Japanese company has infringed upon its patent …
Incyte acquires Ariad’s European operations in $140 million deal
May 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Ariad, Incyte, Operations, buy out, european, iclusig, leukaemia, out-license
Incyte (NASDAQ: INCY) has entered into an agreement with Ariad Pharmaceuticals (NASDAQ: ARIA) that will see the company acquire Ariad’s …
Cell Therapy signs £12.5 million licensing deal with Daiichi Sankyo for heart failure treatment
May 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Daiichi Sankyo, Deals, cell therapy, heart failure, licensing
UK-based Cell Therapy on Tuesday said it has signed a £12.5 million licensing deal with Japan’s Daiichi Sankyo (TYO: 4568) …
Medivation maybe mulling sale as bidding race heats up – Reports
May 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Deals, M&A, MA, Medivation, Pfizer, Sanofi
Cancer drugmaker Medivation (Nasdaq: MDVN) is evaluating a potential sale following the recent string of offers from big pharma firms, …
Takeda secures $38 million grant to develop affordable polio vaccine
May 10, 2016Manufacturing and Production, Research and Development Bill and Melinda Gates Foundation, Gates Foundation, Takeda, Vaccine, access, developing countries, grant, polio
Takeda Pharmaceuticals has received a $38 million grant from the Bill and Melinda Gates Foundation to develop a low-cost polio …
Scottish Medicines Consortium does not back Vertex’ cystic fibrosis drugs Orkambi, Kalydeco
May 10, 2016Manufacturing and Production, Research and Development Kalydeco, Orkambi, SMC, Vertex Pharma, cystic fibrosis, regulation
The Scottish Medicines Consortium did not back two cystic fibrosis therapies from Vertex Pharmaceutical (Nasdaq: VRTX). SMC did not recommend …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
